In a 55‑year‑old woman with anxiety who has tried hydroxyzine pamoate 25 mg (occasionally 50 mg) for insomnia without benefit, what non‑sedating, non‑habit‑forming sleep aid should be recommended?

Trazodone is a reasonable option for this patient after hydroxyzine failure

For this 55-year-old woman with anxiety and insomnia unresponsive to hydroxyzine, trazodone 25-50 mg at bedtime is an appropriate next step, though first-line benzodiazepine receptor agonists (zolpidem, eszopiclone, zaleplon) or low-dose doxepin would be preferred if she has no contraindications.

Why Hydroxyzine Failed

Hydroxyzine (an antihistamine) is not recommended for chronic insomnia treatment 1. The guidelines explicitly state that over-the-counter antihistamines lack efficacy and safety data for chronic insomnia 1. The FDA label confirms hydroxyzine causes significant sedation and has concerning risks including QT prolongation, especially problematic in older adults 2. Your patient's experience—occasional benefit at 50 mg but inadequate sleep improvement—reflects the poor evidence base for antihistamines as hypnotics 3.

Recommended Treatment Algorithm

First-Line Pharmacologic Options (in order of preference):

1. Benzodiazepine receptor agonists (BzRAs): Zolpidem 5-10 mg, eszopiclone 1-3 mg, or zaleplon 5-10 mg at bedtime 1

   • These are the guideline-recommended first-line agents for primary insomnia
   • Non-habit-forming is a relative term—these have lower abuse potential than benzodiazepines but are Schedule IV controlled substances
   • Start at lowest dose; particularly important at age 55

2. Low-dose doxepin 3-6 mg at bedtime 4, 5

   • Specifically FDA-approved for insomnia at these low doses
   • Evidence shows efficacy in older adults with improved sleep latency, total sleep time, and quality
   • No black box warning for suicide at hypnotic doses (unlike higher antidepressant doses)
   • Recommended as first-line in older adults 5

Second-Line Option (Where Trazodone Fits):

1. Trazodone 25-50 mg at bedtime 1
   • Listed as a sedating antidepressant option, especially when comorbid depression/anxiety exists 1
   • Your patient's anxiety history makes this particularly relevant
   • Critical caveat: The 2016 American College of Physicians guideline found insufficient evidence for trazodone efficacy 3, and the VA/DoD 2019 guideline advises against trazodone due to lack of efficacy data 4
   • However, it remains widely used in clinical practice and may help both anxiety and sleep 6

Specific Recommendation for This Patient

Start with low-dose doxepin 3 mg at bedtime, escalating to 6 mg if needed. This is the most evidence-based non-habit-forming option that addresses both sleep onset and maintenance 4, 5.

If doxepin is unavailable or not tolerated, trazodone 25-50 mg is reasonable given her anxiety comorbidity, though acknowledge the weaker evidence base. Recent data shows trazodone 100 mg and doxepin 25 mg have similar efficacy profiles after lower-dose failures 6.

If she specifically wants to avoid antidepressants, then a BzRA (zolpidem 5 mg or eszopiclone 1-2 mg) is appropriate, with clear counseling that these are controlled substances requiring monitoring.

Critical Pitfalls to Avoid

• Do not continue hydroxyzine—it's ineffective and carries cardiac risks 2
• Do not use benzodiazepines (temazepam, lorazepam)—higher abuse potential and cognitive impairment risk outweigh benefits 4
• Avoid antihistamines (diphenhydramine, doxylamine)—poor efficacy, anticholinergic effects, and specifically contraindicated in older adults per Beers Criteria 4
• Always combine with sleep hygiene education and consider referral for CBT-I, which remains the gold standard 3, 7
• Monitor regularly (every few weeks initially) for effectiveness and adverse effects 1
• Use lowest effective dose and attempt to taper when conditions allow 1

The FDA recently issued safety warnings about complex sleep behaviors (sleep-driving, sleepwalking) with BzRAs 4, so counsel patients accordingly if prescribing these agents.